Eptifibatide is supplied as an injectable cyclic heptapeptide active pharmaceutical ingredient whose approved clinical use is intravenous antiplatelet therapy for acute coronary syndrome and percutaneous coronary intervention. Because the molecule undergoes rapid gastrointestinal proteolysis and exhibits negligible peptide permeability across intestinal epithelium, no approved tablet, capsule, or granule dosage form exists. Downstream applications are therefore restricted to parenteral finished-dose manufacture, hospital pharmacy preparation, generic injectable development, analytical method qualification, cold-chain distribution, and investigational product supply. The following scenarios record production-scale handling, regulatory anchors, and process limits without extending into unapproved oral solid-dosage routes.

What Sterility and Particulate Controls Govern Aseptic Fill-Finish of 2 mg/mL Eptifibatide Injection?

Compounding for terminal filtration is carried out in a Grade C environment under EU GMP Annex 1:2022, ISO 14644-1:2015 Class 7, and FDA 21 CFR Parts 210/211. Eptifibatide API is dissolved at 2.0 mg/mL for the 10 mL single-dose vial presentation and at 0.75 mg/mL for the 100 mL single-use infusion bag. The solution also contains 5.25 mg/mL citric acid monohydrate with pH adjustment to 5.35 using sodium hydroxide, and is passed through a 0.22 µm sterilizing-grade hydrophilic polyethersulfone filter before filling. Filling occurs under Grade A unidirectional airflow in a restricted access barrier system or glove-port isolator. Because the cyclic peptide cannot tolerate terminal steam sterilization, filtration is the sole sterilization mechanism, and aseptic process simulations are required with zero positive units across three consecutive runs. Post-fill inspection covers visible particulates per USP 790, subvisible particulates per USP 788, sterility per USP 71, and bacterial endotoxin per USP 85. Container closure integrity is verified by vacuum decay per USP 1207. The terminal presentations are 20 mg/10 mL vials and 75 mg/100 mL infusion bags, both designed for single-dose intravenous administration.

Because eptifibatide is administered as an intravenous bolus followed by continuous infusion in acute coronary syndrome and percutaneous coronary intervention, hospital pharmacy preparation operates under USP 797 low-risk compounded sterile preparation conditions, with aseptic withdrawal conducted in an ISO Class 5 hood. The dosing standards—180 µg/kg bolus and 2.0 µg/kg/min maintenance infusion, reduced to 1.0 µg/kg/min when creatinine clearance is below 50 mL/min—are encoded into smart-infusion pump drug libraries. A 100 kg patient receiving a 180 µg/kg bolus requires 18 mg eptifibatide, equivalent to 9 mL of the 2 mg/mL vial concentrate, leaving minimal residual volume in a 10 mL single-dose vial. For continuous infusion, the 100 mL bag at 0.75 mg/mL is attached directly to a programmable pump with microbore tubing without further dilution. The finished product from the pharmacy workflow is a patient-specific intravenous infusion of 0.75 mg/mL in a 100 mL bag or a bolus syringe containing 18 mg for a 100 kg patient. Physical compatibility data outside the labeled infusion container are limited, and the formulation contains no antimicrobial preservative.

Generic Parenteral Development and Q1/Q2 Equivalence for Eptifibatide ANDA Filings

Regulatory assessment of an eptifibatide generic injection requires pharmaceutical equivalence under 21 CFR 314.94 and sameness of active ingredient, concentration, and excipients under FD&C Act 505(j)(2). The reference listed drug is supplied as 2 mg/mL in 10 mL vials and 0.75 mg/mL in 100 mL bags. The ANDA formulation must match Q1 and Q2 inactive ingredient composition at 5.25 mg/mL citric acid monohydrate and pH 5.35. Downstream scale-up proceeds from small-scale compounding through pilot bioburden-reduction filtration and aseptic filling. Process validation uses three consecutive batches with filter validation per PDA Technical Report 26; bacterial retention on 0.22 µm membranes is demonstrated with Brevundimonas diminuta ATCC 19146 at no less than 10^7 CFU/cm² challenge. A bioequivalence waiver under 21 CFR 320.22(b)(1) may apply for a parenteral solution with Q1/Q2 sameness. The terminal product is a preservative-free, single-dose generic eptifibatide injection for intravenous use, packaged in Type I glass vials with chlorobutyl stoppers and a closed infusion bag presentation.

For pharmacopeial release and stability testing of eptifibatide API, the chromatographic procedure relies on reversed-phase C18 columns with UV detection in the 210–220 nm range, a wavelength region dictated by peptide bond absorption rather than chromophoric side chains. Method validation follows ICH Q2(R1) and USP 621, with accuracy and precision challenged over a linearity range of 80%–120% of the 2.0 mg/mL label claim, corresponding to 1.6–2.4 mg/mL. System suitability solutions are prepared at 2.0 mg/mL nominal and bracketed with 1.6 mg/mL and 2.4 mg/mL solutions. Forced degradation samples are exposed to acid, base, peroxide, and heat according to ICH Q1B to resolve the impurity profile from the parent peptide. Data integrity follows 21 CFR Part 11 for electronic records, and compendial procedure verification follows USP 1225. The terminal output is a validated assay procedure, impurity profile report, and reference standard qualification certificate traceable to USP eptifibatide reference standard.

When Cold Chain Loaded at 2–8 °C Becomes the Dominant Constraint for Finished Distribution

Eptifibatide finished injection is labeled for storage at 2–8 °C and is not formulated with an antimicrobial preservative. Uncontrolled temperature excursion therefore shortens usable shelf life and creates a potential microbial growth vector after first puncture. The formulation addition ratio remains 2 mg/mL for vials and 0.75 mg/mL for infusion bags, with no terminal dilution and no preservative content. Distribution compliance follows WHO Technical Report Series 961 Annex 9 for temperature-sensitive pharmaceutical products, ICH Q1A(R2) for stability commitment, and 21 CFR 211.166 for storage conditions. Cold-chain qualification uses insulated shippers with phase-change materials tested under ISTA 7D summer and winter profiles, with calibrated data loggers placed in each pallet. The finished product must not be frozen; freeze-thaw cycles can generate subvisible aggregates and visible particulates in peptide formulations. The terminal article is a patient-ready injectable maintained within the label-claimed storage range until point of administration.

Within clinical trial supply chains, eptifibatide active pharmaceutical ingredient is sourced from a GMP-certified manufacturing site and released by a Qualified Person against an approved investigational medicinal product dossier under EU GMP Annex 13 and ICH E6(R2). Compliance additionally spans 21 CFR 312 for investigational new drug applications and 21 CFR Parts 50/56 for informed consent and institutional review board oversight. Trial vials and infusion bags are supplied at 2 mg/mL and 0.75 mg/mL, with placebo or comparator product prepared in matching containers to preserve blinding. Primary and secondary packaging operations include randomization code allocation, label printing with unique kit numbers, and temperature-monitored distribution to investigative sites. The terminal output is an investigational medicinal product suitable for double-blind administration in phase I through phase IV protocols, with all release data captured in a clinical trial master file and a product specification file.